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Abstract
Objective: To describe obstetrician-gynecologists’ practices and attitudes related to substance 
use screening in pregnant patients.
Study Design: A 2017 cross-sectional survey assessed U.S. obstetrician-gynecologists’ (n=462; 
response rate=34%) practices (substance use screening frequency and methods) and attitudes 
(practice priority of screening, confidence in treating, and responsibility statements). Chi-squared 
tests and adjusted modified Poisson regression were used to estimate associations between 
practices and attitudes.
Results: Of 353 respondents with screening information, 79% frequently screen for substance 
use and 11% used a validated instrument. Confidence was highest for treating pregnant patients 
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using tobacco (81%). Respondents whose practices make it a high priority to screen for all 
substances were 1.2 times as likely to frequently screen as their counterparts (95% CI: 1.1–1.3).
Conclusions: Four out of five obstetricians-gynecologists reported a high frequency of 
substance use screening in pregnant patients. Findings highlight the importance of increasing 
priority of substance use screening by obstetrician-gynecologists.
Introduction
Approximately 20% of infants are exposed to substances (tobacco, alcohol, marijuana, 
opioids, and other illicit drugs) during pregnancy annually (1). Existing literature 
demonstrates associations between tobacco and alcohol use during pregnancy and respective 
infant outcomes of preterm birth and low birthweight (2–4) and fetal alcohol spectrum 
disorders (5) and birth defects (6, 7). Parallel with the opioid crisis, incidence of neonatal 
abstinence syndrome in the United States has increased (8). Additionally, concern remains 
regarding cannabis use during pregnancy and potential long-term developmental outcomes 
as more states consider legalization of medical and/or recreational cannabis (9–11). Women 
with substance use disorders have additional healthcare needs, such as co-occurring mental 
health conditions like depression or anxiety, and increased risk for infectious diseases (12).
Pregnancy provides a unique opportunity for providing care to women who might not 
otherwise see a physician. In addition, pregnant women may be more interested in receiving 
help to improve health behaviors and likely to modify their behaviors for the benefit of the 
infant (13, 14). Thus, obstetrician-gynecologists are uniquely poised to encourage substance 
cessation and engagement in treatment for substance use disorders during prenatal care. The 
United States Preventive Services Task Force (USPSTF) recommends universal screening of 
pregnant women for tobacco and alcohol use (15, 16). In 2008, the USPSTF found 
inconclusive evidence to recommend screening of pregnant women for illicit substances 
(17); this recommendation is currently being updated (18). A 2015 guideline from the 
American College of Obstetricians and Gynecologists (ACOG) recommends verbal 
screening for tobacco, alcohol, and illicit substances with a validated screening tool (19). 
Additionally, ACOG recommends physicians provide brief intervention for positive 
substance use screens, such as engaging in short conversations with the patient, providing 
feedback, advice, and treatment or referral to treatment in order to improve pregnancy 
outcomes (12, 19–21).
Despite guidelines for screening and management of pregnant women using substances (12, 
19–21), screening rates by obstetrician-gynecologists appear to be declining. A 2000 survey 
of ACOG membership found that 92% of physicians always asked pregnant patients about 
alcohol use during their first visit (22); this proportion fell to 82% in 2010 (23). 
Additionally, the use of validated tools to screen for alcohol use fell from 23% in 2000 to 
11% in 2010 (22, 23). While a majority of obstetrician-gynecologists report screening their 
patients for other illicit substance use during pregnancy (24, 25), a 2011 survey found that 
42% used a validated screening tool to screen for substance use (26). It is unknown whether 
these estimates have changed in the context of the opioid crisis and cannabis legalization. 
Compared to screening and treatment for tobacco and alcohol use during pregnancy, illicit 
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substances present unique screening and treatment challenges and legal considerations that 
may influence obstetrician-gynecologists’ substance use screening practices (12, 19, 27, 28).
The objectives of this study were to (1) describe the frequency and method of substance use 
screening in a sample of obstetrician gynecologists; (2) estimate the association between 
screening frequency and obstetrician-gynecologists’ attitudes (i.e., screening priority, 
confidence in treating, responsibility for screening, awareness of resources, referral and 
treatment obligations, and notifying patients of legal obligations); and (3) identify the 
independent association between screening frequency and attitudes, controlling for 
physician, patient population, and practice characteristics. Understanding health care 
physician attitudes and their associations with screening frequency can inform efforts for 
improving care for substance use during pregnancy.
Materials and Methods
Design
ACOG and Centers for Disease Control and Prevention (CDC) investigators collaboratively 
developed a cross-sectional survey to assess obstetrician-gynecologists’ substance use 
screening frequency and methods, perceptions of priority of routine screening, confidence in 
treating various types of substance use, and responsibility for screening, referral, and 
treatment. Survey content and format was based off of subject matter experts’ input and 
previously conducted surveys of obstetrician-gynecologists. The survey was piloted by five 
obstetrician-gynecologists who were removed from the sampling frame.
The 32-question survey was fielded from March to September 2017 and administered by a 
combined electronic/paper mailing protocol. An email with an online survey link was sent to 
all potential participants. An option to opt-out of the survey was provided to all potential 
participants. Non-responders who did not opt-out received a weekly reminder email for five 
weeks, a mailed questionnaire with a cover letter and a coded return envelope. Finally, non-
responders received an abbreviated questionnaire containing seven critical questions 
(priority of substance use screening by substance, management practices regarding pregnant 
and postpartum women using opioids, years of practice post residency, certification as an 
addiction specialist, board certification in MFM, and insurance coverage of patient 
population) which were identified by the CDC-ACOG team. Since the survey was voluntary, 
completion of a survey was considered consent to participate. ACOG received local IRB 
approval; CDC IRB was not applicable as CDC was not engaged in research and received a 
de-identified dataset. The information collection was approved by the Office of Management 
and Budget (#0920–1168) in accordance with the Paperwork Reduction Act.
Participants
ACOG membership includes 95% of board-certified obstetrician-gynecologists in the United 
States holding active medical licenses and in medical practices focused on women’s health. 
Both Collaborative Ambulatory Research Network (CARN) members (29), practicing 
ACOG fellows who had indicated interest in participating in survey research, and non-
CARN members were sampled. Out of 1,400 current CARN members, 750 were randomly 
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selected. An additional 750 non-CARN members were selected using proportionate 
stratified sampling by district. Random samples were taken from each of the 12 ACOG 
districts. Thus, within each district, each fellow had an equal probability of selection.
Measures
Survey questions relevant to the current analysis assessed: (I) frequency and method of 
substance use screening, (II) priority of routine screening for specific substances, (III) 
confidence in treating for specific substances, and (IV) physician perceived responsibility 
(Table 1). Other survey questions used in this analysis included physician (sex, race, board 
certification, and years of practice), patient population (percentage of patient’s race 
identified as white and Medicaid enrollees), and practice (practice type, average number of 
new pregnant patients per month, region, and location) characteristics.
Frequency of screening was dichotomized into high (‘always’ or ‘usually’) and low 
(‘sometimes’, ‘rarely’, ‘never’; Table 1). In alignment with ACOG guidelines that 
recommend screening pregnant women for all substances (tobacco, alcohol, cannabis, 
opioids (illicit and prescription use), and other illicit drugs), we combined all substance 
types to create comprehensive variables to be used in the adjusted model. ‘High priority for 
routine screening for all substances’ was defined as respondents who answered ‘high 
priority’ to screening for all seven substances in their practice (tobacco, alcohol, cannabis, 
illicit substances, prescription opioids, non-medical use of prescription opioids, and non-
medical use of other prescription medications). ‘Confident in treating women using various 
substances’ was defined as respondents who reported feeling ‘confident’ or ‘very confident’ 
that they could appropriately treat patients using tobacco, alcohol, cannabis, or opioids. 
Additional categorizations of survey responses can be found in Table 1.
Analyses
We calculated demographic frequencies of respondents and questions on substance use 
screening. Questions on frequency of screening was only included on the long survey, thus 
respondents with missing information on frequency of substance use screening were 
excluded from this analysis. Non-response bias was assessed to determine if demographic 
characteristics (region, age, and sex) differ between respondents and non-respondents. 
Pearson chi-squared tests assessed the association between reported screening frequency and 
attitudes towards priority of substance-specific routine screening, confidence in treating for 
specific substances, and responsibility statements. The independent association of high 
screening frequency for all substance use with perceived high practice priority for routine 
screening for substances, confidence in treating all substances, and feeling responsible for 
screening, controlling for physician, patient population, and practice characteristics was 
assessed with a Poisson regression with a robust error variance, or Modified Poisson 
Regression (30). Controlling for all of these variables, we also assessed whether or not the 
association between high priority for routine screening and substance use screening 
frequency differed by individual substance type. A 2-tailed probability of <0.05 was 
considered statistically significant. Data were analyzed with Stata software (Release 14. 
College Station, TX: StataCorp LP).
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Results
The overall response rate for the survey was 34% (n=462). We received 293 responses from 
CARN members (44% response rate) and 169 responses from non-CARN members (25% 
response rate); 156 participants opted-out of the survey. These response rates may be 
indicative of CARN members’ pre-indicated interest in responding to surveys. Of the 
respondents who answered the demographic questions, 63% were female, 81% self-
identified as white, and 12% were board-certified in maternal-fetal medicine. On average, 
respondents had 21 years of practice since residency. The majority of respondents were from 
group practices, with an average of 35 pregnant patients each month. An estimated 73% of 
respondents had more than a quarter of their patients enrolled in Medicaid. Respondents 
were distributed across the U.S.; over 90% of respondents practiced in urban or suburban 
regions (Table 2). Analyses revealed no significant difference between respondents and non-
respondents by gender or age, but respondents were more likely to be from the Midwest and 
the West than non-respondents (p<0.01). Of the 462 respondents, 16.5% (n=76) responded 
only to the abbreviated questionnaire and 7.1% (n=33) did not answer the questions 
regarding frequency of substance use screening, totaling 23.6% (n=109) that did not answer 
the question of interest. Thus, the final analytical sample included 353 respondents.
Frequency and Method of Screening for Substance Use
Overall, 79% of respondents reported high screening frequency for substance use among 
their pregnant patients. The most common method of obtaining pregnant patient’s substance 
use was a physician asking the patient (80%; Figure 1). Among respondents whose practices 
used a questionnaire to assess substance use, 11% reported using a validated screening 
instrument. A non-validated standard in-house screening instrument was used by 13% of 
respondents, and 76% of respondents reported that their practice does not use a standard 
screening instrument.
Priority of Routine Screening for Substance Use
Overall, about three-quarters of respondents consider routine screening for tobacco (77%), 
alcohol (77%), and illicit substance use (74%) to be a high priority in their practice (Table 
3). Over half of respondents consider routine screening of pregnant patients for prescription 
opioid use (55%), non-medical use of prescription opioids (61.4%), and non-medical use of 
other prescription medications (61.4%) to be a high priority in their practice. Half (53%) of 
respondents consider routine screening for cannabis a high priority in their practice. 
Compared to those who do not frequently screen, respondents who frequently screen for 
substance use among pregnant patients were significantly more likely to report their practice 
considers it a high priority to screen for illicit substances (78% vs. 55%; p<0.01), 
prescription opioid use (63% vs. 28%; p<0.01), non-medical use of prescription opioids 
(68% vs. 37%; p<0.01), cannabis (58% vs. 34%; p<0.01), and non-medical use of other 
prescription medications (67% vs. 40%; p<0.01). There was no difference in perceived 
priority of screening for tobacco (p=0.05), or alcohol use (p=0.41) by frequency of 
substance use screening.
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Confidence in Treating Substance Use
Overall, 81% of respondents reported that they felt confident in treating pregnant patients 
using tobacco (Table 3). An estimated 60% and 62% of respondents felt confident in treating 
pregnant patients using alcohol and cannabis, respectively. An estimated 37% of respondents 
felt confident in treating pregnant patients using opioids (illicit, prescription, and non-
medical use). Compared to those who do not frequently screen, respondents who frequently 
screen for substance use among pregnant patients were significantly more likely to report 
feeling confident in treating pregnant patients using tobacco (84% vs. 70%; p=0.02), 
cannabis (66% vs. 44%; p<0.01), and opioids (42% vs. 21%; p<0.01). There was no 
difference in screening frequency by confidence in treating pregnant patients using alcohol 
(p=0.09).
Responsibility Statements
Among all respondents, 94% and 88% agreed that it was their responsibility to screen 
pregnant patients for substance use and be aware of local resources available to patients with 
substance use disorders, respectively (Table 3). Thirty-one percent of respondents agreed 
that it was their responsibility to ensure that pregnant patients entered treatment after 
referral. An estimated 86% of respondents agreed that it was their responsibility to notify 
patients of legal or medical obligation for testing of substance use. Compared to those who 
do not frequently screen, respondents who frequently screen for substance use among 
pregnant patients were significantly more likely to feel responsible for screening (97% vs. 
86%; p<0.01) and being aware of local resources available for patients with substance use 
disorders (91% vs. 75%; p<0.01). Screening frequency was not statistically different for 
responsibility statements related to ensuring patients enter treatment after referral (p=0.82) 
or notifying patients of legal obligation for substance use testing (p=0.51).
Factors Associated with High Frequency of Screening
Controlling for physician, patient population, and practice characteristics, perception that 
screening for all substances was a practice priority was associated with greater prevalence of 
high screening frequency (aPR= 1.2; 95% CI: 1.1–1.3; n=281)(Table 4). Additional analyses 
assessed whether results differed by individual substances. A high screening frequency was 
associated with high screening priority for illicit drugs, prescription opioids, and non-
medical use of prescription opioids and other drugs (respectively, aPRs: 1.2 (95% CI: 1.0–
1.4), 1.3 (95% CI:1.1–1.5), 1.3 (95% CI: 1.1–1.4), and 1.2 (95% CI: 1.1–1.4)), but not for 
tobacco, alcohol, and cannabis (respectively, aPRs: 1.1 (95% CI: 0.9–1.1), 0.9 (95% CI: 0.9–
1.1), 1.1 (95% CI: 1.0–1.3)).
Discussion
Among our sample of obstetrician-gynecologists, 4 in 5 reported a high screening frequency. 
The most common method for substance use screening was the physician asking the patient; 
however, only 1 in 10 respondents indicated using a validated screening instrument. More 
respondents considered tobacco and alcohol screening to be a high priority than other 
substances. Most respondents felt confident treating pregnant patients using tobacco (81%), 
but only a third felt confident in treating pregnant patients using opioids (37%). The majority 
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of respondents felt a responsibility to screen for substance use during pregnancy and to be 
aware of local resources available for patients with substance use disorders. Perceptions that 
routine screening for all types of substance use was a high priority in the respondent’s 
practice was associated with a 1.2 increase in the prevalence of a high screening frequency 
after adjusting for physician, patient population, and practice characteristics.
ACOG recommends universal screening for substance use at the first prenatal visit via verbal 
screening (12, 19) to avoid missed cases, discrimination and/or bias based on race/ethnicity 
or class, and stigma (12, 31). Maintaining a non-judgmental approach is recommended for 
inclusive disclosure, and screening should be done in partnership with women to facilitate 
receptiveness of treatment (12, 19). While biologic samples provide objective toxicology 
evidence, they do not distinguish occasional users from those with substance use disorder or 
those on treatment (17), are often fraught with issues related to substances’ half-lives and 
detection window (32), and do not provide the patient the opportunity to self-disclose.
Physician self-reported use of validated screening instruments in this study is similar to 
previous research that finds a low utilization of validated screening tools even when the 
majority of obstetrician-gynecologists ask their patients about alcohol use and illicit drugs 
(22–26). Utilization of verbal validated screening tools, such as 4P’s, NIDA Quick Screen, 
and CRAFFT to identify drug and alcohol use among pregnant women is recommended by 
ACOG (12). A recent study validated five commonly used screening tools against biological 
samples and found that sensitivity and specificity for each screening tool differed by 
substance and that no tool had both high sensitivity and specificity (33).
A similar study to identify an optimal screening tool for substance use in pregnancy is 
ongoing (https://projectreporter.nih.gov/reporter.cfm: R01 DA041328). Screening behaviors 
may reflect a number of reasons, such as reimbursement coverage for screening, the burden 
of incorporating an additional screen into a patient’s visit, and the need to fully assess the 
clinical utility of standardized questionnaires for pregnant populations who use illicit 
substance screening during pregnancy (17). Universal screening with validated tools may be 
promoted via increased dissemination of tools, reimbursement for their use or as part of a 
value-based payment to a hospital/system, and continued support to integrate screening into 
practices.
Higher screening priority and confidence in treating for alcohol and tobacco may reflect 
higher prevalence of use during pregnancy and evidence that screening, brief intervention, 
and referral to treatment (SBIRT) is effective for these substances (15, 16). Nonetheless, 
approximately 1 in 5 respondents neither consider tobacco screening to be a high priority in 
their practice nor feel confident in treating it, highlighting gaps that could be addressed 
through practice administration’s policies and/or physician educational opportunities. Low 
physician confidence in treating pregnant women using opioids may be indicative of a lack 
of training in addiction medicine and/or knowledge of the benefits of medication assisted 
treatment for treatment of opioid use disorder. Physicians that more frequently advise 
medication assisted treatment for opioid use disorder were more likely to be confident in 
treating pregnant patients using opioids (34). ACOG guidelines advise physicians to be 
knowledgeable about local resources for substance use treatment and to provide a referral to 
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brief therapy or additional treatment to patients who need additional services (12). Published 
clinical experience indicates that personal communication with specialists at drug addiction 
clinics may lead to a more timely appointment and that discussions with the patient to 
address barriers with attendance may be helpful (35), thereby improving adherence to 
treatment. Given an overwhelming unmet treatment need for women with substance use 
disorders in the U.S. (36), obstetrician-gynecologists have a role in offering effective 
treatment, for example by providing behavioral interventions for tobacco cessation (15) and 
obtaining waivers to prescribe buprenorphine to treat opioid use disorder (12, 15). Practice 
patterns of obstetrician-gynecologists related to opioid use during pregnancy and postpartum 
are found in a companion analysis (34).
Strengths and Limitations
This study has several limitations. First, the response rate (34%) was low, ranging from 44% 
among CARN members to 25% among non-CARN members. CARN members pre-indicate 
interest in responding to surveys and may be more likely to carve out time to respond to 
surveys. Data collection included online and paper options were used to increase the 
response rate. There was significant difference in U.S. regions between respondents and 
non-respondents, but not for sex and age; thus, our results may not be generalizable to all 
obstetrician-gynecologists. Screening practices of non-responders to the survey or to the 
frequency of screening question are unclear. Nonresponse bias is less problematic in 
physician populations compared to other survey populations (37). Our estimates of screening 
frequency may be overestimated due to social desirability bias and an interest in substance 
use disorders and screening among our respondents. Second, to align with ACOG’s 
universal screening for substance use during pregnancy, we used aggregated measures of 
substance use screening priority and confidence in treatment in the model, not allowing for 
assessment of the association between frequency and predictors by each substance. 
However, we explored these differences and noted that physicians who reported high priority 
for illicit drug screening were more likely to have a high screening frequency. Third, our 
sample was not robust enough to examine whether attitudes and screening practices differ 
among respondents practicing in states with and without policies criminalizing or requiring 
report of suspected substance use during pregnancy. Overall, these data are based on self-
report and rely on respondents’ interpretation of knowledge, attitudes, and practices of 
substances included in the survey (e.g., confidence in treatment asked about opioid use and 
did not specify illicit versus prescription use).
Conclusions
In conclusion, the majority of obstetrician-gynecologists reported a high frequency of 
screening pregnant women for substance use, but many do not use a validated screening tool. 
After controlling for physician, patient population, and practice characteristics, respondents 
who considered routine screening a priority of their practice had a 1.2 times higher 
prevalence of high screening frequency. Findings suggest a need to understand the best 
method of gaining disclosure on substance use from pregnant women. Additionally, public 
health strategies are needed to increase training and education for obstetrician-gynecologists 
to improve confidence in treating for substance use.
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Figure 1. 
How Practice Obtains Information about Pregnant Patients’ Substance Use, Survey of 
American College of Obstetrician and Gynecologists Members, 2017 (n=375)
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Table 1.
Questionnaire items from the survey of American College of Obstetricians and Gynecologists members, 2017 
(n=462)
Theme Question Answer Options Categorization
I. Frequency and 
Method of 
Screening
1. In your practice, how often do you screen for substance use 
among pregnant patients (including illicit use and non-medical 
use of prescription opioids)?
A. Usually
B. Always High frequency
C. Sometimes
D. Rarely
E. Never
Low frequency
2 How does your practice obtain information about pregnant 
patients’ substance use (including illicit use and non-medical 
use of prescription opioids)?
A. A physician asks the 
patient
B. Other staff asks the 
patient
C. Patient fills out 
questionnaire
D. Biologic test
E. Other (please specify)
F. My practice does not 
screen for substance use
N/A
3. If your practice uses a questionnaire to assess substance use, 
please check the one most frequently used:
A. My practice does not use 
a standard screener
B. Other (please specify)
My practice does 
not use a standard 
screening 
instrument
B. Other (please specify)
Standard in-house 
screening 
instrument
C. 4P’s Plus© Screen for 
Substance Use in Pregnancy
D. 5Ps Prenatal Substance 
Abuse Screen
E. Substance Use Risk 
Profile – Pregnancy (SURP-
P)
F. CRAFFT screener for 
adolescent and young adult 
substance abuse
G. Wayne Indirect Drug Use 
Screener (WIDUS)
H. National Institute on 
Drug Abuse (NIDA) 
Quickscreen
Validated 
screening 
instrument
II. Priority of 
Screening
To what extent is any routine screening of the following among 
pregnant patients in your practice a priority?
1. Prescription opioid use
2. Non-medical use of prescription opioids (i.e. using opioids 
for reasons other than prescribed)
3. Non-medical use of other prescription medications 
(benzodiazepines, barbiturates, etc.)
4. Illicit substance use (heroin, cocaine, hallucinogens, etc.
5. Cannabis use
6. Tobacco use
7. Alcohol use
A. Not a priority
B. Moderate priority
C. High Priority
N/A
III. Confidence in 
Treatment
Do you feel confident that you can appropriately treat your 
pregnant patients who are using the following substances?
1. Opioids
2. Cannabis
3. Tobacco
4. Alcohol
A. Not confident Not confident
B. Somewhat confident Somewhat 
confident
C. Confident
D. Very confident Confident
IV. Responsibility
Please indicate how much you agree or disagree with each 
statement.
1. It is my responsibility to screen all pregnant patients for 
substance use
A. Strongly disagree
B. Disagree
C. Neutral
Neutral/Disagree
D. Agree Agree
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Theme Question Answer Options Categorization
2. It is my responsibility to be aware of local resources available 
for patients with substance use disorders.
3. It is my responsibility to make sure patients enter treatment 
after I refer them.
4. When there is a legal or medical obligation for testing 
patients for substance use, it is my responsibility to notify 
patients of this testing.
E. Strongly Agree
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Table 2.
Characteristics of Obstetrician-Gynecologist Respondents and Practices, Survey of American College of 
Obstetricians and Gynecologists Members, 2017
Physician, Patient Population, and Practice Characteristics Total Answered %
Physician identifies as female 349 63.0
Physician identifies as non-Hispanic white 347 81.0
Physician is Maternal Fetal Medicine (MFM) board certified 346 11.6
Years since physician’s residency completed, Mean ±SD 410 20.5 ± 10.7
% of patients race/ethnicity white, Mean ±SD 326 52.6 ± 24.9
>25% of patients enrolled in Medicaid 409 72.6
Practice type 350
 Solo private practice 10.9
 Non-solo practice1 89.1
Number of pregnant patients in month, Mean ± SD 331 34.5 ± 72.2
U.S. region of practice 346
 Midwest 25.1
 Northeast 22.0
 South 29.5
 West 23.4
Location of practice 347
 Urban 63.7
 Suburban 28.2
 Rural/Military 8.1
1
Includes partnership, group, hospital, university, HMO/Staff model, and other practices
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Table 3.
Obstetrician-Gynecologists’ Perceptions of Priority of Screening, Confidence in Treatment, and Feelings of 
Responsibility by Frequency of Substance Use Screening for Pregnant Patients, Survey of American College 
of Obstetricians and Gynecologists Members, 2017
Frequency of Substance Use Screening
Respondent Perceptions and Attitudes N Total, % High Frequency, % Low Frequency,% p-value1
Perceived practice routine screening for…
Tobacco Use 350 0.05
High Priority 76.6 79.1 66.7
Moderate Priority 21.4 19.4 29.2
Low Priority 2.0 1.4 4.2
Alcohol Use 351 0.41
High Priority 76.6 77.7 72.6
Moderate Priority 21.1 20.5 23.3
Low Priority 2.3 1.8 4.1
Illicit Substance Use 351 <0.01
High Priority 73.5 78.4 54.8
Moderate Priority 20.8 18.4 30.1
Low Priority 5.7 3.2 15.1
Prescription Opioid Use 349 <0.01
High Priority 55.3 62.5 27.8
Moderate Priority 34.1 31.4 44.4
Low Priority 10.6 6.1 27.8
Non-medical use of prescription Opioids 350 <0.01
High Priority 61.4 67.9 37.0
Moderate Priority 28.3 26.4 35.6
Low Priority 10.3 5.8 27.4
Cannabis Use 348 <0.01
High Priority 53.2 58.2 34.3
Moderate Priority 36.5 33.8 46.6
Low Priority 10.3 8.0 19.2
Non-medical use of other prescription medications 347 <0.01
High Priority 61.4 67.2 39.7
Moderate Priority 29.1 25.9 41.1
Low Priority 9.5 6.9 19.2
Confidence in treating pregnant patients using…
Tobacco 340 0.02
Confident 81.2 84.3 69.9
Somewhat Confident 13.8 11.2 23.3
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Frequency of Substance Use Screening
Respondent Perceptions and Attitudes N Total, % High Frequency, % Low Frequency,% p-value1
Not Confident 5.0 4.5 6.9
Alcohol 340 0.09
Confident 60.3 63.3 49.3
Somewhat Confident 27.7 25.8 34.3
Not Confident 12.1 10.9 16.4
Opioids 340 <0.01
Confident 37.1 41.6 20.6
Somewhat Confident 34.7 34.8 34.3
Not Confident 28.2 23.6 45.2
Cannabis 340 <0.01
Confident 61.5 66.0 44.4
Somewhat Confident 23.8 21.3 33.3
Not Confident 14.7 12.7 22.2
It is my responsibility to…
Screen all pregnant patients for substance use 340 <0.01
Agree 94.4 96.7 85.9
Neutral/Disagree 5.6 3.4 14.1
Be aware of local resources available for patients with 
substance use disorders 340 <0.01
Agree 87.6 91.0 74.7
Neutral/Disagree 12.4 9.0 25.4
Make sure patients enter treatment after referral 340 0.82
Agree 31.3 31.0 32.4
Neutral/Disagree 68.7 69.0 67.6
If applicable, notify patients of legal or medical obligation for 
testing for substance use 340 0.51
Agree 85.6 86.2 83.1
Neutral/Disagree 14.5 13.8 16.9
1Column differences assessed with Pearson chi-squared tests
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Table 4.
Characteristics Associated with Physicians Reporting a High Frequency of Substance Use Screening Among 
Pregnant Patients, Survey of American College of Obstetricians and Gynecologists Members, 2017 (n=281)
Physician Characteristics aPR1 (95% CI)
Perceives screening for seven types of substances to be a high priority in their practice2 1.2 (1.1–1.3)
Confident in treating patients using various substances3 1.1 (1.0–1.2)
Feels responsible for substance use screening 1.3 (0.9–1.9)
Physician female sex 1.0 (0.9–1.2)
Physician white race/ethnicity 1.0 (0.9–1.2)
MFM board certified 1.1 (0.9–1.3)
<20 Years since residency completed 1.0 (0.9–1.2)
Patient Population Characteristics aPR* (95% CI)
Patients white race/ethnicity
 0–25% Ref.
 26–50% 1.0 (0.8–1.3)
 51–100% 1.2 (0.9–1.4)
Patients on Medicaid
 0–25% Ref.
 26–50% 1.0 (0.9–1.2)
 51–100% 1.1 (0.9–1.3)
Practice Characteristics aPR* (95% CI)
Practice Type
 Solo private practice 0.8 (0.6–1.0)
 Non-solo practice Ref.
≥15 New Pregnant Patients per Month 1.1 (0.9–1.2)
U.S. Region
 Northeast Ref.
 Midwest 0.9 (0.8–1.0)
 South 0.9 (0.8–1.1)
 West 0.9 (0.8–1.0)
Location
 Urban Ref.
 Suburban 1.0 (0.9–1.2)
 Mid-Sized Town/Rural/Military 1.0 (0.9–1.2)
Bold aPR indicates significant at p<0.05
1Adjusted prevalence ratio calculated using Poisson regression with a robust error variance, adjusted for physician, patient population, and practice 
characteristics
2
Physician perceives that their practice makes it high priority to screen for prescription opioid use, non-medical use of prescription opioids, non-
medical use of other prescription medications, illicit substance use, marijuana use, tobacco use or alcohol use
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3
Physician feels confident in treating pregnant patients using opioids, marijuana, tobacco, or alcohol
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